trial

A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression

NCTId NCT00128479
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 443 (actual)
Sponsored by Corcept Therapeutics
Primary completion 2007-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
443 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2004-09
Primary completion
2007-01
Eligibility
ALL · 18 Years · 75 Years

Interventions & indications

Drugs
Mifepristonemifepristone 600 mgmifepristone 1200 mg

Sponsors

Corcept TherapeuticsLead Sponsor

Investigators

1
Katherine Beebe, PhDStudy Director

Sites

44 total
Little Rock, United StatesCerritos, United StatesFountain Valley, United StatesNational City, United StatesOceanside, United StatesRiverside, United StatesTorrance, United StatesWestminster, United StatesHamden, United StatesWashington D.C., United StatesFort Lauderdale, United StatesJacksonville, United States

Linked catalysts

1
A United States Study of the Safety and Tolerability of Corlux for Psychotic Sym — primary completion2007-01

Facts & assertions

4 sourced
Enrollment
443
Phase
PHASE3
Primary Completion Date
2007-01
Status
COMPLETED
relationships
The graph out of here
drug
Mifepristone
drug
mifepristone 600 mg
drug
mifepristone 1200 mg
drug
lead_sponsor
Corcept Therapeutics
company
indication
Major Depressive Disorder
indication
Psychotic Disorders
indication
Depressive Disorder, Major
indication
investigator
Katherine Beebe, PhD
person